Publication Name	World Journal of Gastroenterology
Manuscript ID	16497
Country	Italy

Received	2015-01-20 08:56
Peer-Review Started	2015-01-21 08:28
To Make the First Decision	2015-02-10 15:30
Return for Revision	2015-02-12 14:07
Revised	2015-02-22 00:37
Second Decision	2015-04-13 16:17
Accepted by Journal Editor-in-Chief	2015-04-14 01:25
Accepted by Executive Editor-in-Chief	2015-04-17 15:11
Articles in Press	2015-04-17 16:15
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-05-26 19:37
Publish the Manuscript Online	2015-06-18 17:32

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Somatostatin analogs for gastric carcinoids: for many, but not all
Manuscript Source	Invited Manuscript
All Author List	Sara Massironi, Alessandra Zilli and Dario Conte
Funding Agency and Grant Number
Corresponding Author	Sara Massironi, MD, PhD, Gastro¬enterology and Endoscopy Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milano, Italy. sara.massironi@policlinico.mi.it
Key Words	Neuroendocrine tumors; Atrophic gastritis; Octreotide; Lanreotide; Enterochromaffin-like cells; Carcinoid tumors
Core Tip	The management of type-Ⅰ gastric carcinoids is still debated because of their relatively benign course against the fact that they can have a heterogeneous unpredictable biological behavior. Even if in most cases their endoscopic treatment is effective, in some particular cases it may not be sufficient. The potential role of somatostatin analogs (SSAs) has been reported in several recent studies. However, neither a standard indication nor a specific schedule of treatment with defined dosage and duration have been adopted to date. Because of the high cost of SSAs, clear-cut indications for this therapy are required in order to avoid any overtreatment.
Publish Date	2015-06-18 17:32
Citation	Massironi S, Zilli A, Conte D. Somatostatin analogs for gastric carcinoids: For many, but not all. World J Gastroenterol 2015; 21(22): 6785-6793
URL	http://www.wjgnet.com/1007-9327/full/v21/i22/6785.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i22.6785

Full Article (PDF)	WJG-21-6785.pdf
Full Article (Word)	WJG-21-6785.doc
Manuscript File	16497-Review.doc
Answering Reviewers	16497-Answering reviewers.pdf
Audio Core Tip	16497-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	16497-Conflict-of-interest statement.pdf
Copyright License Agreement	16497-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	16497-Language certificate.pdf
Peer-review Report	16497-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	16497-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	16497-Scientific misconduct check.pdf
Scientific Editor Work List	16497-Scientific editor work list.pdf